ABBVIE INC.Company logo

United States of America (US)

OpenCorporation rating: 22.29 on 100

Ranking 2022: 495 on 604 companies


Primary and secondary NACE classification:
• Manufacture of pharmaceutical preparations (2120)
• Research and experimental development on biotechnology (7211)

Company description

The company is a research-based pharmaceuticals business that is engaged in the discovery, development, manufacture, and sale of a line of pharmaceuticals and biologics worldwide. It was established in 2012 and conducts business activities from its registered office in North Chicago, Illinois, United States.The company's principal products are HUMIRA for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, juvenile idiopathic arthritis, and Crohn's disease as well as ulcerative colitis, and axial spondyloarthritis; Kaletra used in the treatment of HIV infection; Lupron used for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty, and for the preoperative treatment of patients with anemia; Synagis, a syncytial virus prevention product used to protect infants from severe respiratory disease; AndroGel for the treatment of adult males who have low testosterone; sevoflurane, an anesthesia product; Zemplar for the prevention and treatment of secondary hyperparathyroidism associated with stage 3, 4, or 5 chronic kidney disease; Synthroid used for the treatment of hypothyroidism; Creon for the treatment of pancreatic exocrine insufficiency; and TriCor, Trilipix, Simcor, and Niaspan for the treatment of dyslipidemia. It also has a pipeline of new medicines consisting of approximately 20 compounds or indications in Phase II or Phase III development in medical specialties, such as immunology, renal care, hepatitis C, women's health, oncology, and neuroscience, including multiple sclerosis and Alzheimer's disease. In addition, the company offers other products, such as Duodopa, a levodopa-carbidopa intestinal gel for the treatment of advanced Parkinson's disease. It sells its products directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers.

[…] show more

OpenCorporation questionnaire

The read only version of the questionnaire submitted to this company is publicly available: view questionnaire.

Indicators

The rating is calculated on the following metrics (for more information visit the section Methodology).

score (max is 100)
15
8.7
40
60.4
0
0
43.2
60
25.3

YTD Rankings history

HQ and subsidiaries

ABBVIE INC.
loading subsidiaries

* The position of map pins may not reflect the exact location

About this evaluation

This company did not compile the OpenCorporation questionnaire, for this reason this evaluation was made only on data available to the project staff.

Claims and support from the company

If as a company manager or official of ABBVIE INC. you want to enter in touch with our staff, provide more information to OpenCorporation or get an account to access and compile the company questionnaire, please write an email to support@opencorporation.org.

Tell the OpenCorporation team

If you detect corporate behavior in contrast with what emerges from the OpenCorporation corporate rating card in your country, or in the branch where you work, report it to info@opencorporation.org so that our team can take it in account.

More evaluations

This company has other evaluations:

Permament links

The link below will always open the 2022 evaluation:

2022: https://www.opencorporation.org/en/ranking/abbvie-inc/2022    url copied

The link below will always open the latest evaluation available:

Last: https://www.opencorporation.org/en/ranking/abbvie-inc/last    url copied